Brinzolamide
FDA-approved product (suspension/drops, ophthalmic), marketed as Azopt, Brinzolamide.
- Registered studies
- 50+
- Lab records
- 4
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Glaucoma
- Ocular hypertension
- Open-angle glaucoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Carbonic anhydrase inhibitors
- FDA pharmacologic class
- Carbonic Anhydrase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA47.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis83.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- M. tuberculosis: measured active in 4 of 4 lab records
Show the 4 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Brinzolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
- Enalapril MaleateExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure
NCT01484951 · start 2011-05
Registered record
- Registry ID
- NCT01484951
- Conditions
- Glaucoma
- Interventions
- Brinzolamide 1% and timolol 0.5% fixed combination eye drops
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2012-03
- Enrolment
- 74
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaInterventionBrinzolamide 1% and timolol 0.5% fixed combination eye dropsPhasePhase 4Registry statusCompletedEfficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%
NCT01297517 · start 2011-02
Registered record
- Registry ID
- NCT01297517
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1%; Brimonidine tartrate ophthalmic solution, 0.2%
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2012-03
- Enrolment
- 1,001
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventionBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1%; Brimonidine tartrate ophthalmic solution, 0.2%PhasePhase 3Registry statusCompletedFixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension
NCT01357616 · start 2010-11
Registered record
- Registry ID
- NCT01357616
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension; Brinzolamide 1% ophthalmic suspension; Timolol 0.5% ophthalmic solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-11
- Completion
- 2013-01
- Enrolment
- 328
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventionBrinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension; Brinzolamide 1% ophthalmic suspension; Timolol 0.5% ophthalmic solutionPhasePhase 3Registry statusCompletedPatient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma
NCT01471158 · start 2010-09
Registered record
- Registry ID
- NCT01471158
- Conditions
- Glaucoma
- Interventions
- Brinzolamide/Timolol Maleate Fixed Combination (AZARGA); Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-09
- Completion
- 2011-05
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaInterventionBrinzolamide/Timolol Maleate Fixed Combination (AZARGA); Dorzolamide/timolol Maleate Fixed Combination (COSOPT)PhasePhase 4Registry statusCompletedComparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
NCT01111890 · start 2010-04
Registered record
- Registry ID
- NCT01111890
- Conditions
- Glaucoma; Ocular Hypertension
- Interventions
- Azarga (brinzolamide 1% / timolol 0.5%); Cosopt (dorzolamide 2% / timolol 0.5%)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2011-07
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma; Ocular HypertensionInterventionAzarga (brinzolamide 1% / timolol 0.5%); Cosopt (dorzolamide 2% / timolol 0.5%)PhasePhase 4Registry statusCompletedELAZOP Switching Study in Korea
NCT01055366 · start 2010-03
Registered record
- Registry ID
- NCT01055366
- Conditions
- Open Angle Glaucoma
- Interventions
- Elazop (Azarga)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2011-12
- Enrolment
- 96
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen Angle GlaucomaInterventionElazop (Azarga)PhasePhase 4Registry statusCompletedSafety and Efficacy of Brinzolamide/Brimonidine Fixed Combination
NCT00961649 · start 2009-10
Registered record
- Registry ID
- NCT00961649
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1%; Brimonidine tartrate ophthalmic solution, 0.2%; Vehicle
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2009-10
- Completion
- 2010-02
- Enrolment
- 195
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventionBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1%; Brimonidine tartrate ophthalmic solution, 0.2%; VehiclePhasePhase 2Registry statusTerminatedEfficacy and Safety of Adding Azarga to Prostaglandin Monotherapy
NCT00966576 · start 2009-07
Registered record
- Registry ID
- NCT00966576
- Conditions
- Glaucoma
- Interventions
- Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2010-08
- Enrolment
- 47
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaInterventionBrinzolamide/Timolol Maleate Fixed Combination (AZARGA)PhasePhase 4Registry statusCompletedSafety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT00761995 · start 2009-02
Registered record
- Registry ID
- NCT00761995
- Conditions
- Glaucoma; Ocular Hypertension
- Interventions
- Azopt; Cosopt
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-02
- Completion
- 2010-07
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma; Ocular HypertensionInterventionAzopt; CosoptPhasePhase 4Registry statusCompletedTravoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT
NCT00767494 · start 2008-10
Registered record
- Registry ID
- NCT00767494
- Conditions
- Glaucoma; Ocular Hypertension
- Interventions
- Travoprost/Brinzolamide fixed combination; Azopt; Travatan
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2008-10
- Completion
- 2009-02
- Enrolment
- 17
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma; Ocular HypertensionInterventionTravoprost/Brinzolamide fixed combination; Azopt; TravatanPhasePhase 3Registry statusTerminatedArgon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma
NCT00980473 · start 2007-09
Registered record
- Registry ID
- NCT00980473
- Conditions
- Glaucoma
- Interventions
- Argon Laser Iridoplasty; Travatan/ Timolol/Azopt
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2007-09
- Completion
- Not recorded
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaInterventionArgon Laser Iridoplasty; Travatan/ Timolol/AzoptPhasePhase 3Registry statusUnknownIOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00527501 · start 2007-08
Registered record
- Registry ID
- NCT00527501
- Conditions
- Open-angle Glaucoma; Ocular Hypertension
- Interventions
- Travoprost/brinzolamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-08
- Completion
- 2007-12
- Enrolment
- 136
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-angle Glaucoma; Ocular HypertensionInterventionTravoprost/brinzolamidePhasePhase 2Registry statusCompletedIOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy
NCT00382226 · start 2006-09
Registered record
- Registry ID
- NCT00382226
- Conditions
- Glaucoma
- Interventions
- Azopt
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2007-08
- Enrolment
- 195
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaInterventionAzoptPhasePhase 4Registry statusCompletedBrimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
NCT00440141 · start 2006-07
Registered record
- Registry ID
- NCT00440141
- Conditions
- Glaucoma; Ocular Hypertension
- Interventions
- latanoprost 0.005% eye drops and brimonidine 0.1% eye drops; latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-07
- Completion
- 2007-03
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma; Ocular HypertensionInterventionlatanoprost 0.005% eye drops and brimonidine 0.1% eye drops; latanoprost 0.005% eye drops and brinzolamide 1.0% eye dropsPhasePhase 4Registry statusCompletedA Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00326092 · start 2006-05
Registered record
- Registry ID
- NCT00326092
- Conditions
- Open-angle Glaucoma; Ocular Hypertension
- Interventions
- Brinzolamide/Timolol
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2006-08
- Enrolment
- 88
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-angle Glaucoma; Ocular HypertensionInterventionBrinzolamide/TimololPhasePhase 2Registry statusCompleted